TrianglePhase I Trial of BCMA-TGF-BETA CAR-T… (NCT05976555)
Phase I Trial of BCMA-TGF-BETA CAR-T Cell… trial for Multiple Myeloma (NCT05976555). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Multiple myeloma keeps coming back. CAR T cells against a marker called BCMA can clear it for a time, but most patients eventually relapse.
The idea: armor the cells against the signal the tumor uses to switch them off.
Myeloma bone marrow is rich in TGF-beta, a molecule that quiets immune cells. Here, a patient's T cells receive the BCMA receptor plus a change that makes them insensitive to TGF-beta, so they keep working where ordinary CAR T cells are dampened. The cells are grown with interleukin-7 and -15, favoring younger, longer-lived cells.
An early dose-finding trial in adults after three or more prior therapies, including prior BCMA drugs.
Binod Dhakal leads it at the Medical College of Wisconsin. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.